Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Impact of Nusinersen on Public Health Service Utilization and Associated Costs in Children with Spinal Muscular Atrophy

EF 2020-21

Résumé
The aim of my proposed Master's research project is to evaluate the impact of nusinersen on public health service utilization and associated costs in children with spinal muscular atrophy (SMA) using ICES data.SMA is a rare neurodegenerative disorder affecting anterior horn cells in the spinal cord, leading to progressive muscle weakness and atrophy. It is the leading cause of infant mortality in developed countries. Nusinersen is a novel disease-modifying medication that can improve motor function and overall survival, but comes with a price tag of almost 1 million dollars for the first year of therapy. There are currently no provincial or national data on public healthcare utilization and costs of patients treated with nusinersen. For patients with SMA, however, these data are paramount because of the extraordinary cost of treatment. We hypothesize that both utilization and costs are diminished in children with SMA treated with nusinersen compared to those who were not. We will carry out a retrospective cohort study using linked population-based, health administrative data housed at the Institute for Clinical Evaluative Sciences (ICES). We will import a provincial cohort of children receiving nusinersen in Ontario. Not only will our study help inform allocation of limited resources, but it will also help us understand the impact of new policies and emerging therapies, such as the recent approval for SMA newborn screening in Ontario and novel therapies awaiting Health Canada approval (eg. gene therapy, slice modifier therapy). As the clinical landscape of SMA evolves, we hope that our study will help guide evidence-based policy-making to ensure high quality care of children with SMA.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449699
Name
Shi Jenny Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Impact of Nusinersen on Public Health Service Utilization and Associated Costs in Children with Spinal Muscular Atrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Canada; Health Administrative Ices Data; Morbidity And Mortality; Nusinersen; Ontario; Pediatric; Population-Based; Population-Based Health And Policy Planning; Public Health Service Costs; Public Health Service Utilization; Retrospective Cohort Study; Spinal Muscular Atrophy
Abstract
The aim of my proposed Master's research project is to evaluate the impact of nusinersen on public health service utilization and associated costs in children with spinal muscular atrophy (SMA) using ICES data.SMA is a rare neurodegenerative disorder affecting anterior horn cells in the spinal cord, leading to progressive muscle weakness and atrophy. It is the leading cause of infant mortality in developed countries. Nusinersen is a novel disease-modifying medication that can improve motor function and overall survival, but comes with a price tag of almost 1 million dollars for the first year of therapy. There are currently no provincial or national data on public healthcare utilization and costs of patients treated with nusinersen. For patients with SMA, however, these data are paramount because of the extraordinary cost of treatment. We hypothesize that both utilization and costs are diminished in children with SMA treated with nusinersen compared to those who were not. We will carry out a retrospective cohort study using linked population-based, health administrative data housed at the Institute for Clinical Evaluative Sciences (ICES). We will import a provincial cohort of children receiving nusinersen in Ontario. Not only will our study help inform allocation of limited resources, but it will also help us understand the impact of new policies and emerging therapies, such as the recent approval for SMA newborn screening in Ontario and novel therapies awaiting Health Canada approval (eg. gene therapy, slice modifier therapy). As the clinical landscape of SMA evolves, we hope that our study will help guide evidence-based policy-making to ensure high quality care of children with SMA.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shi, Jenny Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~